Still, the broader trend toward earlier initiation reflects a larger paradigm shift in diabetes care, where patients increasingly benefit from the use of GLP-1s early in their treatment journey
In reality, the surge of interest in medications like Ozempic and Mounjaro has highlighted something Ive seen for years in my private nutritional therapy practice: for many, the struggle with binge eating and emotional eating is deeply physiological, yet has an element of imbalance in hunger and fullness signals
This highlights the need to balance the benefits and disadvantages of such use and to regularly reassess the need for continued proton pump inhibitor treatment. The research was published in The British Medical Journal (BMJ)
As a physician in Obesity Medicine, having managed patients on GLP-1 therapies for over a decade across both the US and India, a few thoughts to gently add
Interestingly enough, patients with higher baseline ASCVD risk with tirzepatide therapy showed significantly more reductions in risk [3]
SU, sulfonylurea